THE HOLLOW AISLE

The American Supplement Investigation — Book Two

The Regulatory Gap, the Science of Risk, and the Business of Belief

Joy Meier, Pharm.D.

with Robert W. Coleman, MS Pharm.

Coleman Publishing

Copyright © 2026 Joy Meier and Robert W. Coleman. All rights reserved.

No part of this publication may be reproduced, distributed, or transmitted in any form or by any means without prior written permission of the author, except for brief quotations in critical reviews or articles.

This book is a work of investigative nonfiction. Every factual claim is sourced to peer-reviewed research, federal regulatory documents, or government data, as identified in the bibliography. This book does not provide personalized medical advice; readers should consult a qualified healthcare professional before beginning, changing, or discontinuing any supplement or medication.

The Hollow Aisle is Book Two of The American Supplement Investigation, a three-part evidence-based series. Book One, What the Label Doesn’t Tell You, and Book Three, Prove It, complete the investigation.

Preface

Book One of this investigation ended with a question I didn’t answer: how much of what’s sitting in an American medicine cabinet has ever been tested with anything resembling the rigor of the beta-carotene trials at all? This book is where I answer it.

The answer starts with a fact that still catches people off guard the first time they hear it stated plainly, even after Book One has already prepared them for it: a dietary supplement can reach a store shelf in the United States without its manufacturer ever having to prove, to anyone, that it works. Not to a regulator. Not to a scientific panel. Not, in most cases, even to a court, unless something has already gone wrong. That isn’t a loophole some company found. It’s the law, written that way on purpose in 1994, and never substantially revisited since — even as the market it governs grew twentyfold underneath it.

I spent sixteen years as Director of Clinical Pharmacy Services at the VA Palo Alto Health Care System, much of it building the kind of medication safety infrastructure that exists precisely because drugs are required to prove themselves before they reach a patient. Watching that same rigor simply not apply, by design, to an entire adjacent category of products people take for their health is what pulled me into this investigation in the first place.

This book follows the money and the language as closely as it follows the law. Part III walks through the regulatory structure itself — what a label can and can’t tell you, what a claim like “supports immune function” is and isn’t allowed to imply, and what happens, and doesn’t happen, when something goes wrong with a product already on shelves. Part IV takes on the assumption that sits underneath so much of the marketplace: that “natural” and “safe” are the same idea, when the pharmacology says otherwise. Part V follows the business itself — who profits, how the language of science gets borrowed for marketing, and what happens when a personality with a large following becomes, functionally, a source of medical advice for millions of people with no clinical training required of them at all. Part VI turns the lens on my own profession, asking honestly whether physicians and pharmacists are equipped to have the conversations this book argues patients deserve.

None of this is an argument that every company in this industry is acting in bad faith, and I want to say that as directly as I said the parallel point in Book One. Most of what you’ll read here isn’t a story of fraud. It’s a story of a system that never required anyone to prove very much in the first place, operating exactly as designed, at a scale nobody anticipated when the design was written.

If Book One gave you the tools to evaluate a claim, this book shows you what those tools reveal when you point them at the system actually selling the claim to you. Book Three will take both sets of tools and apply them to real diseases, real information ecosystems, and real cases — and close with a specific recommendation for what should change. This book is where the case for that recommendation gets built.

Robert W. Coleman, MS Pharm.

PART III — THE REGULATORY GAP

Chapter 1 — Medicine Before the Medicine Cabinet

Two products sit on two different shelves in the same drugstore. One is a prescription statin, lowering cholesterol for a patient with heart disease. The other is a bottle of red yeast rice, marketed for “cholesterol support,” sitting a few aisles over in the supplement section — and containing, depending on the batch, a compound chemically identical to the active ingredient in that same statin. One of these products underwent years of clinical trials, regulatory review, and manufacturing oversight before a patient ever swallowed it. The other, in most cases, did not. Neither the shelf they’re sitting on nor the price tag in front of them tells you which is which.

This chapter is about the fork in the road that put those two products in such different positions, and about a single question worth asking before anything else in this book: who, exactly, had to prove that either of them works?

How a drug reaches a patient

Before a new prescription drug can be sold in the United States, its manufacturer has to take it through a process that typically spans years and can cost hundreds of millions of dollars: laboratory research, animal testing, then three phases of human clinical trials measuring safety and effectiveness in progressively larger groups of people, all submitted to the FDA for review before the agency will approve the drug for sale at all. After approval, the FDA continues to monitor manufacturing facilities and post-market safety reports for as long as the drug remains on the market. Every step in that sequence exists because a drug is presumed, by law, to be unsafe and unproven until its maker demonstrates otherwise.

How a supplement reaches the same patient

A dietary supplement follows none of that sequence. Under the Dietary Supplement Health and Education Act of 1994 — DSHEA, the law Chapter 1 of Book One introduced and this chapter examines directly — a manufacturer can formulate a new supplement, put it into production, and begin selling it to the public without submitting any evidence of safety or effectiveness to the FDA beforehand, and in most cases without even notifying the agency the product exists. The law presumes the opposite of what it presumes for a drug: a supplement is treated as safe unless and until the FDA can demonstrate, after the fact, that it isn’t.

This is not a case of one agency enforcing a law poorly. It’s two entirely different legal starting points, applied to two products that, as the red yeast rice example shows, can sometimes contain the same active compound.

What DSHEA actually requires

DSHEA does impose some obligations, and it’s worth being precise about what they are, because the gap here is easy to overstate in one direction and understate in the other. Manufacturers must follow Good Manufacturing Practice regulations covering identity, purity, and consistent production — genuine requirements, enforced through facility inspections. Labels must not claim a supplement diagnoses, treats, cures, or prevents a specific disease; violating that line can draw FDA enforcement. And a newly introduced dietary ingredient — one not marketed before October 1994 — does require the manufacturer to notify the FDA and provide some evidence of safety, though nowhere near the depth a new drug requires.

What’s absent is any requirement to prove the product does what its marketing implies it does. A structure/function claim like “supports heart health” needs no clinical evidence behind it at all — only a disclaimer, printed in small type, noting that the FDA has not evaluated the claim.

Two Regulatory Paths

Picture this as two parallel tracks. On the drug track: laboratory research, animal studies, three phases of human trials, FDA review and approval, then ongoing post-market surveillance — a process that runs, on average, a decade or more before a single prescription is filled. On the supplement track: formulation, a Good Manufacturing Practice-compliant production run, a label written by the manufacturer itself, and a shelf. The supplement track can run in weeks. Both tracks end at the same kind of store, often the same aisle, sometimes — as with red yeast rice — with genuinely overlapping chemistry.

Key Finding: The difference between a drug and a supplement is not, primarily, a difference in what either product contains. It is a difference in what the law required someone to prove before either one reached you.

The next chapter turns to the one document most consumers actually rely on to make sense of any of this: the label itself. What can it really tell you, and — just as importantly — what is it not required to say at all?

Chapter 2 — The Label

Pick up almost any supplement bottle and turn it around. You’ll find a “Supplement Facts” panel that looks, at a glance, reassuringly similar to the Nutrition Facts label on a box of cereal — the same clean grid, the same familiar percentages, the same air of standardized, regulated disclosure. That resemblance is doing a great deal of persuasive work, and it’s worth taking the label apart panel by panel to see how much of that reassurance actually holds up.

Serving size and the number games it enables

Every claim on the panel is calculated per serving, and the manufacturer sets what a serving is. A product can appear to deliver an impressively large dose of an ingredient while quietly defining a “serving” as two or three capsules rather than one — a legal practice, and one worth checking before comparing the apparent potency of two competing products.

Ingredients, dosage, and the proprietary blend loophole

For most individual ingredients, the label must disclose the specific amount per serving. But a large share of supplements — particularly in the sports nutrition and energy categories — list ingredients inside a “proprietary blend,” disclosing the blend’s total weight while keeping each ingredient’s individual amount a trade secret. A label can legally tell you that a blend contains 1,500 milligrams of six named ingredients combined, without telling you whether the ingredient actually driving the marketed effect makes up 1,400 of those milligrams or 40 of them.

Percent Daily Value — and the ingredients it can’t cover

The %DV column works reasonably well for nutrients with an established federal daily value, like vitamin C or calcium. It’s frequently absent entirely for herbs, botanicals, and novel compounds, for the simple reason that no such standard exists for them — which means the panel’s most familiar, most reassuring column often goes blank for precisely the ingredients a buyer most needs context to interpret.

“Other ingredients” and warnings

Below the main panel, an “other ingredients” list discloses fillers, binders, coatings, and flavorings — worth a glance for anyone managing an allergy or a sensitivity, since these components can include allergens with no obligation to feature them as prominently as the marketed active ingredients. Warnings, when present, tend to be narrowly scoped — a pregnancy caution, an anticoagulant interaction note — and, as Chapter 5 in Book One’s companion volume on risk will make clear when we return to interactions in Part IV of this book, a warning’s absence should never be read as a finding of safety. It may simply mean no one has looked closely enough to document a risk yet.

Structure/function claims and the disclaimer nobody reads

A claim like “supports immune function” or “promotes healthy aging” is called a structure/function claim, and it requires no clinical evidence submitted to anyone before it goes on a label. It requires only one thing: a standardized disclaimer, printed in small type, almost always in the same place, almost always skipped by the reader’s eye — “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” That sentence is the single most important piece of text on the entire label, and it is very likely the one you have looked at least.

Anatomy of a Supplement Label

Laid out as a single annotated diagram, the label breaks into these zones: the serving size the manufacturer chose; the ingredient panel, split between individually disclosed amounts and anything folded into a proprietary blend; the %DV column, present for some ingredients and structurally absent for others; the other-ingredients list; any warnings; the structure/function claim on the front of the package; and the disclaimer required to accompany it. Reading a label well means checking all seven zones, not just the one printed in the largest font on the front of the bottle.

Investigator’s Note — Read the Fine Print

The next time you pick up a supplement, try reading the label in a specific order: start with the disclaimer, then the proprietary blend line if one exists, then the serving size, and only then the marketing claim on the front of the package. Reading in that order — regulatory reality first, marketing promise last — is the single most practical habit this chapter can offer you.

The label tells you what a manufacturer is required to disclose. It says far less about what a manufacturer is permitted to imply without disclosing anything at all — and that’s a very different, and in some ways more consequential, set of questions. The next chapter takes on the language of the claims themselves.

Chapter 3 — The Claim That Sounds Like a Cure

“Supports healthy blood sugar already within a normal range.” Read that phrase quickly, the way most shoppers do standing in an aisle, and it sounds like a promise about diabetes management. Read it slowly, the way a regulator has to, and it’s a sentence engineered to promise almost nothing at all — support, not treatment; healthy levels, not diabetic ones; already normal, not elevated. This chapter is about the considerable distance between what a claim like that is legally permitted to say and what a reasonable shopper, reading quickly in a well-lit aisle, is likely to hear.

Why the line exists

Federal law draws a sharp distinction between two kinds of health claims. A disease claim — asserting that a product diagnoses, treats, cures, mitigates, or prevents a specific disease — turns a product into an unapproved drug the moment it’s made, and can trigger real enforcement. A structure/function claim — asserting that a product supports or maintains a normal bodily structure or function — requires no clinical evidence at all, only the disclaimer from Chapter 2. The entire art of supplement marketing copy, for a great many products, is finding language that sits as close as possible to the disease-claim line without technically crossing it.

Five phrases, decoded

“Supports heart health” implies protection against heart disease. It legally claims only that an ingredient plays some role in normal cardiovascular function — a claim so broad it could be made, with equal legal safety, about drinking water.

“Supports immune function” implies fewer colds, faster recovery, stronger resistance to illness. It legally claims only that an ingredient is involved in some aspect of how the immune system operates — a claim that says nothing about whether taking more of it produces any measurable improvement in how often or how severely you actually get sick.

“Promotes healthy aging” implies a product slows or reverses some effect of growing older. It legally claims nothing specific enough to be tested at all, which is precisely what makes it durable across an enormous range of products with no ingredients in common.

“Supports cognitive function” implies improved memory, focus, or protection against decline. It legally claims only that an ingredient relates in some way to normal brain function — not that a measurable difference in memory, attention, or dementia risk has ever been demonstrated for the product making the claim.

“Helps maintain healthy blood sugar”, as the opening of this chapter showed, is carefully restricted to levels already within a normal range — a population, notably, that includes most people who don’t have diabetes or prediabetes at all, and excludes, by its own careful wording, the population most likely to be shopping for exactly this kind of help.

The Language of Suggestion

Picture these claims arranged on a spectrum from “legally cautious” to “consumer impression,” with a visible gap between the two ends for every single phrase. The manufacturer’s legal team writes to the left end of that spectrum. The label design, product name, package imagery, and surrounding marketing consistently push a shopper’s actual impression toward the right end — and no law requires the distance between those two ends to be disclosed anywhere on the package.

What the Consumer May Hear vs. What the Claim Actually Says

None of these five phrases is a lie in the narrow legal sense the law was written to police. Each of them is, however, an invitation to hear more than the sentence actually says — and an invitation that costs the manufacturer nothing if you accept it. The next chapter turns from the claim itself to what happens after a product carrying one of these claims is already on the shelf: who, if anyone, is watching what happens next.

Chapter 4 — Who Watches the Marketplace?

More than 80,000 products, sold through tens of thousands of retail locations and an uncountable number of websites, reaching tens of millions of consumers a year. No premarket review of any of them. The question this chapter asks is the one that follows naturally from that picture: once a product is already on the shelf, what actually happens if it turns out to be dangerous?

How a problem gets discovered

Almost never through proactive inspection. The system runs, overwhelmingly, on after-the-fact reporting. A consumer or a physician notices a suspected reaction and files a report — sometimes voluntarily, sometimes because a manufacturer is legally required to forward “serious” adverse event reports it receives — into the FDA’s Center for Food Safety and Applied Nutrition Adverse Event Reporting System, known as CAERS. Between 2004 and 2021, CAERS received more than 79,000 adverse event reports tied to dietary supplements. A widely cited analysis of just the 2004–2013 window found more than 15,000 reports that included 339 deaths and nearly 4,000 hospitalizations. Researchers who study the system describe it as an undercount, not an overcount — most adverse events are never reported at all, and among those that are, many are never successfully traced back to the specific supplement that caused them.

From complaint to action

Once a pattern emerges — from CAERS reports, from a state health department, from a journalist’s investigation, or occasionally from routine surveillance testing — the FDA’s options are narrower than most consumers assume. The agency can issue a warning letter to a manufacturer, demanding corrective action. It can publish a public safety alert. It can pursue a court injunction against products found to be genuinely dangerous. What it generally cannot do, unlike its authority over food, is compel a supplement recall directly in most circumstances — the great majority of supplement recalls are technically voluntary, negotiated with a manufacturer after the FDA has documented a problem serious enough to make refusal commercially untenable.

Contamination, mislabeling, and hidden ingredients

The violations that surface most often fall into a few recurring categories: contamination with heavy metals, bacteria, or unlisted allergens; mislabeling that misstates ingredients or dosages; and — among the most serious — products found to contain undisclosed active pharmaceutical ingredients. The FDA maintains an ongoing public warning list of products, overwhelmingly in the weight-loss, sexual-enhancement, and bodybuilding categories, found to be secretly spiked with prescription drug compounds, sometimes at doses well outside any established safe range, marketed the entire time as “all-natural.”

Imported products and online marketplaces

Enforcement grows considerably harder once a product originates overseas or moves through a third-party online marketplace rather than a traditional retail supply chain. A product manufactured abroad and sold directly to a U.S. consumer through an online storefront can pass through very little of the oversight — thin as it already is — that applies to a product moving through an established domestic retailer, and can be difficult for any single agency to trace back to a responsible party at all.

From Consumer Complaint to Regulatory Action

The realistic sequence looks like this: a consumer or physician notices harm → a report reaches CAERS, if it reaches anyone at all → the FDA looks for a pattern across many such reports, since a single report rarely triggers action on its own → if a pattern is confirmed, a warning letter or public alert follows → a recall, if one happens, is usually negotiated rather than compelled. Every arrow in that sequence depends on the one before it actually happening — and, as the adverse-event numbers above suggest, a great many real harms never make it past the first arrow at all.

Evidence Spotlight — A Product Recall

FDA public warning lists for supplements tainted with hidden pharmaceutical ingredients read, case after case, the same way: a weight-loss or sexual-enhancement product, marketed as entirely natural, found on laboratory testing to contain an undisclosed prescription drug compound — sometimes at a dose exceeding what a doctor would ever prescribe. The product was on shelves and websites, unlabeled as anything but natural, until testing caught up with it after the fact. Post-market surveillance, at its best, is still surveillance that happens after consumers have already been exposed.

Post-market enforcement can only respond to harm that’s already been documented. The next chapter turns to a question that sits upstream of enforcement entirely: whether “natural” was ever a reasonable proxy for “safe” in the first place.

PART IV — THE SCIENCE OF RISK

Chapter 5 — Natural Does Not Mean Safe

Foxglove is a wildflower. It grows in gardens across the country, entirely natural, entirely unmanufactured. It is also the original source of digitalis, a compound so powerful in its effect on the heart that it has been used both to treat heart failure and, at the wrong dose, to stop a heart altogether. Nothing about foxglove being natural made it gentle. What made digitalis usable as medicine was precise dosing, careful monitoring, and decades of pharmacological study — the exact apparatus that a structure/function supplement claim, as Chapter 3 showed, is never required to have behind it.

Where the word did its quiet work

“Natural” became shorthand for “safe” for an understandable, if mistaken, reason: it draws a contrast with “synthetic” and “manufactured,” categories that carry associations with industrial chemistry and its risks. But safety was never actually a function of a compound’s origin. It’s a function of toxicity, dose, and how a substance interacts with a specific person’s body — questions that apply with equal force to a compound extracted from a plant and one synthesized in a lab.

The regulatory record says the same thing

Three episodes make the point concretely. Ephedra, an entirely natural botanical stimulant marketed for weight loss and athletic performance through the 1990s, was linked to a documented pattern of serious cardiovascular events — heart attacks, strokes, and sudden deaths — severe enough that the FDA banned it from dietary supplements in 2004, the only time to date the agency has used this authority to remove an entire ingredient category from the market. Comfrey, an herbal remedy with centuries of traditional use, contains pyrrolizidine alkaloids capable of causing serious, sometimes irreversible liver injury, and is now restricted or banned in numerous countries for internal use. And aristolochic acid, found in some traditional botanical preparations, has been linked to kidney failure and, in some documented cases, urinary tract cancers — a risk serious enough that several countries have banned botanicals known to contain it outright.

None of these compounds was synthetic. All three occurred naturally, exactly the way “natural” on a modern supplement label implies should mean something reassuring.

Dose, pharmacology, and who’s vulnerable

Toxicology has a foundational principle worth carrying forward into every remaining chapter of this book: the dose makes the poison. Nearly any substance, taken at a high enough amount, becomes harmful — while a compound genuinely dangerous at one dose can be safe, even beneficial, at another. This is precisely why pharmacology exists as a discipline: not to distrust nature, but to determine, compound by compound, exactly where that line sits. A natural compound has no exemption from this principle. It simply may not have been studied closely enough yet for anyone to know exactly where its line falls — a genuine unknown, not a reassurance.

Some populations carry that uncertainty at greater cost than others: pregnant and breastfeeding women, whose supplement risk profile can differ sharply from the general population’s; older adults managing multiple medications simultaneously; people with impaired liver or kidney function, who may not clear a compound at the rate a dosing recommendation assumes; and children, for whom almost no supplement dosing has been specifically studied at all.

Natural → Chemical → Dose → Effect

Every natural compound is a chemical — that’s simply what a compound is, however it was sourced. Its effect on the body depends on its specific chemistry and the dose delivered, not on whether it grew in a field or was synthesized in a facility. Tracing that chain — natural source, actual chemical structure, dose delivered, physiological effect — is the habit this chapter asks you to build, and it will recur through most of what remains in this book.

Key Finding: Nature produces both medicines and poisons. “Natural” is not a safety test — it’s a description of where a compound came from, and says nothing on its own about what it does once it’s inside you.

The next chapter moves from the general principle to the specific, documented harms: what actually happens when a supplement goes wrong, and how often it does.

Chapter 6 — When Supplements Harm

Before this chapter goes any further, a note on how it’s built. It would be easy to fill a chapter like this one with individual horror stories — a single case report, vivid and alarming, presented as though it proved the whole category dangerous. That approach would be a disservice to the same evidence standards Book One spent seven chapters building. Everything in this chapter is drawn from registries and peer-reviewed research that track patterns across many documented cases, not from isolated reports used to imply a risk larger than the evidence actually supports.

What the liver injury registries actually show

The clearest documented signal comes from the Drug-Induced Liver Injury Network, or DILIN, a research consortium funded by the National Institutes of Health that has tracked cases of serious liver injury attributed to medications and supplements since 2003. Across DILIN’s referral centers, the share of documented drug-induced liver injury cases attributed to herbal and dietary supplements rose from 7 percent to 20 percent between 2004 and 2013 — a statistically significant increase, published in the journal Hepatology. By 2017, that 20 percent figure had held, and more recent reviews describe it as still accounting for roughly one in five drug-induced liver injury cases studied through the network.

The pattern within that data is worth sitting with. DILIN researchers found that liver injury linked to bodybuilding supplements, while producing prolonged jaundice in young men, resulted in no deaths or liver transplants in their study population. Liver injury linked to non-bodybuilding herbal and dietary supplements — taken predominantly by middle-aged women, often for weight loss or general wellness — was significantly more severe, resulting in death or the need for a liver transplant at more than four times the rate seen with conventional medications in the same study.

When the label itself is part of the problem

One additional DILIN finding belongs in this chapter rather than the earlier one on labeling, because it shows the two problems compounding each other. Researchers investigating liver injury linked to green tea extract found that of 73 implicated products, 29 — 40 percent — did not list green tea extract or its active compounds on the label at all, despite laboratory testing confirming its presence. A patient and their physician trying to identify the cause of an unexplained liver injury could review that patient’s supplement labels line by line and never find the actual culprit listed.

Drug interactions and bleeding risk

Beyond liver injury, one of the best-documented and most clinically significant supplement risks involves interaction with anticoagulant and antiplatelet medications — a category we’ll examine in full in the next chapter. For now, it’s enough to flag the general shape of the problem: several common supplements, including high-dose vitamin E, fish oil, and certain herbal products like ginkgo, have documented blood-thinning properties of their own, and combining them with a prescribed anticoagulant can compound bleeding risk in ways neither the supplement label nor, frequently, the prescribing physician’s chart accounts for.

How supplement risk actually reaches a patient

The realistic pathway looks like this: a product enters the market with no premarket safety review → it may or may not accurately disclose everything it contains, as the green tea extract finding shows → a consumer combines it with existing medications or health conditions with no systematic interaction check built into the purchase → an adverse effect occurs → it may or may not ever be connected back to the supplement, reported to CAERS, or captured by a registry like DILIN. Each step in that chain is a place where a real harm can go undetected — which is precisely why the documented numbers in this chapter should be read as a floor, not a ceiling.

Patient Perspective

The physicians who contribute cases to registries like DILIN describe a recurring pattern in their own words: a patient presents with unexplained liver enzyme abnormalities, standard questioning about “medications” turns up nothing, and it’s only a specific, direct follow-up question — “are you taking any vitamins, herbs, or supplements?” — that surfaces the actual cause. The gap isn’t always the patient’s failure to mention it. It’s often a clinical conversation that never thought to ask.

The interactions this chapter has only introduced deserve a chapter of their own, given how routinely supplements and prescription medications end up in the same medicine cabinet. That’s where we turn next.

Chapter 7 — The Interaction Nobody Told You About

In 2000, physicians reported a pattern serious enough to publish in The Lancet: heart transplant patients on cyclosporine, a drug that suppresses the immune system precisely enough to prevent organ rejection, began showing dangerously low cyclosporine levels — low enough that several patients experienced acute transplant rejection. The cause traced back to something entirely legal, widely available, and, to most of the patients involved, entirely unremarkable: St. John’s Wort, an herbal supplement several of them had started taking for mood support, purchased without a prescription and, in most cases, without ever mentioning it to their transplant team.

This chapter is about that gap — the space between a supplement a patient sees as harmless because it doesn’t require a prescription, and the very real pharmacological effect it can have on medications that do.

How interactions actually happen

Supplements interact with prescription drugs through the same basic mechanisms drugs use to interact with each other: by inducing or inhibiting the liver enzymes responsible for metabolizing a medication, by adding a pharmacological effect on top of the drug’s own, or by altering absorption in the digestive tract. St. John’s Wort induces a liver enzyme system that many important drugs depend on for their normal breakdown — which is precisely how it lowered cyclosporine to dangerous levels, and why it’s separately documented to reduce the effectiveness of oral contraceptives and several chemotherapy agents.

Anticoagulants and antiplatelet drugs

Warfarin, one of the most widely prescribed anticoagulants and a medication whose safe use I spent a considerable part of my clinical career managing, is exquisitely sensitive to outside influence. Vitamin K-rich foods and supplements can counteract its effect; fish oil, high-dose vitamin E, and ginkgo each carry their own independent blood-thinning properties that can compound warfarin’s effect and elevate bleeding risk. None of this requires a patient to take an unusual dose or an exotic product — it requires only combining an ordinary supplement with an ordinary prescription, unmonitored.

Diabetes and blood pressure medications

Chromium, bitter melon, and cinnamon supplements are all marketed with blood-sugar claims of the kind Chapter 3 examined, and several have documented, independent blood-glucose-lowering effects — which can compound a diabetes medication’s effect and produce dangerous hypoglycemia rather than the intended “support.” Certain herbal supplements carry similar independent effects on blood pressure, capable of interacting with prescribed antihypertensives in ways that push a well-controlled patient’s blood pressure too low.

Immunosuppressants, chemotherapy, and sedatives

Beyond the cyclosporine case that opened this chapter, St. John’s Wort and several other botanicals are documented to interact with chemotherapy agents through the same liver-enzyme mechanism, with the potential to reduce a cancer treatment’s effectiveness at exactly the moment its full strength matters most. Sedating supplements — melatonin, valerian, kava — can compound the effect of prescribed sedatives, sleep aids, or anti-anxiety medications, raising the risk of excessive sedation in combinations a patient may never think to mention to a prescriber because neither substance, on its own, seems risky.

Prescription Drug + Supplement = Possible Interaction

The pattern across every category in this chapter is the same: a supplement with a genuine, independent pharmacological effect, combined with a prescription medication that shares or opposes that effect, in a patient and a prescriber who frequently have no idea the combination exists at all — because, as the next chapter will show, neither side of that conversation is well set up to ask about it.

Professional Perspective

Medication reconciliation — the standard clinical process of reviewing everything a patient takes — was built around prescriptions and over-the-counter drugs. It was not built, historically, with the assumption that a patient might also be taking eight or ten unregulated products with genuine pharmacological activity. Closing that gap requires both sides: a clinician who asks directly and specifically about supplements, not just “medications,” and a patient willing to bring the full contents of that medicine cabinet from Chapter 1 of Book One to the appointment, not just the prescription bottles.

Every interaction in this chapter depends on a substance’s dose — and on assuming that “more” is either harmless or a straightforward path to more benefit. The next chapter takes on that assumption directly.

Chapter 8 — The Dose Makes the Difference

Iron is essential. Without enough of it, a person becomes anemic, fatigued, and unwell. Iron is also one of the leading causes of fatal poisoning in young children in the United States — because a bottle of adult iron supplements, left within reach, can deliver a toxic dose to a small child from just a handful of tablets. The same element sits on both sides of that sentence, essential and dangerous, separated by nothing but dose.

Recommended intake versus everything above it

Every essential nutrient has a recommended intake — an amount established, generally through decades of nutritional research, to meet the needs of most healthy people. Above that sits a considerably larger range that toxicologists call the therapeutic or supplemental range, and above that, for many nutrients, sits a documented Tolerable Upper Intake Level — a ceiling past which risk of harm begins to climb. The existence of that ceiling is itself worth pausing on: if more were always simply better, nutrition science would have no reason to define an upper limit for anything at all.

Why fat-soluble vitamins carry special risk

Water-soluble vitamins — C and the B-complex vitamins — are, for the most part, excreted in urine when intake exceeds what the body needs, which limits how much can accumulate from typical supplementation. Fat-soluble vitamins — A, D, E, and K — behave differently: they’re stored in fatty tissue and the liver, and can accumulate over time to genuinely toxic levels, particularly with sustained high-dose supplementation rather than a single excessive dose.

Vitamin A toxicity — hypervitaminosis A — can produce liver damage with chronic high-dose use, and carries a well-documented risk of serious birth defects when taken at high doses during pregnancy, which is why prenatal vitamin formulations are specifically capped well below general over-the-counter vitamin A products. Vitamin D, taken at sustained high doses beyond the upper intake level, can raise blood calcium to levels serious enough to affect the heart and kidneys — a genuine risk that has grown more relevant as vitamin D supplementation has become dramatically more popular over the past two decades.

Minerals carry the same principle

Selenium, an essential trace mineral, produces a well-documented toxicity syndrome — selenosis — at chronic high intakes, marked by hair and nail changes and, in more severe cases, nerve damage. Iron, as this chapter’s opening illustrated, is acutely dangerous in overdose in a way most consumers never associate with a nutrient they think of as simply healthy. Both minerals sit exactly where Chapter 5 said any compound sits: essential at one dose, harmful at another, with no exemption granted by how natural or nutritionally necessary the substance is.

The Dose–Response Curve

Picture a curve rather than a line: too little of an essential nutrient causes deficiency and harm on the left side of the curve; an adequate range in the middle supports normal function; and, for a meaningful number of nutrients, harm reappears on the right side of the curve at sufficiently high, sustained intake. “More support” implied by a marketing claim assumes the curve only ever goes up and to the right. For a considerable number of the nutrients supplements are built from, it doesn’t.

This chapter closes Part IV of this investigation. Together, Chapters 5 through 8 have made a single case in four parts: naturalness says nothing about safety, documented harms are real and likely undercounted, interactions with ordinary prescriptions are common and rarely screened for, and dose determines outcome as much for a vitamin as for any prescription drug. Part V turns from the science of risk to the economics of belief — who profits from all of this, and how.

PART V — THE BUSINESS OF BELIEF

Chapter 9 — Follow the Money

A bottle of supplements typically costs a fraction of its retail price to actually manufacture — the capsule, the raw ingredient, the bottle, and the label together often represent a modest share of what a customer eventually pays. The rest of that price funds something else entirely: marketing, distribution, retail margin, and, increasingly, one of several business models built specifically around converting belief into recurring revenue. This chapter follows that money through each of them.

Manufacturing and retail

A large share of the supplement industry doesn’t manufacture its own products at all. Contract manufacturers produce the same formulations, sometimes from the same production lines, for dozens of competing brands, which then differentiate themselves almost entirely through label design, claims, and marketing rather than through any meaningful difference in what’s inside the bottle. Traditional retail then adds its own margin on top, often substantial, before a product ever reaches a shelf.

Direct-to-consumer and the subscription model

The rise of direct-to-consumer supplement brands has shifted much of the industry away from one-time retail purchases and toward subscription “auto-ship” models, which convert an initial purchase into a recurring monthly charge a customer has to actively cancel rather than actively renew. This shift matters financially in a specific way: a subscription customer’s lifetime value to a company is calculated not on a single sale, but on months or years of recurring charges — which raises the return on every dollar spent acquiring that customer in the first place, including the dollars spent on the influencer and affiliate marketing this book examined in Chapter 2 of Book One.

Affiliate marketing

An affiliate marketer — including the influencers Book One’s Chapter 2 discussed — typically earns a commission on every sale traced back to their unique link, commonly in a range from roughly 10 to 50 percent of the sale depending on the product category and platform. That commission is paid regardless of whether the product delivers any benefit to the buyer, which means an affiliate’s financial incentive to recommend a product is entirely disconnected from the product’s actual effectiveness — a structural fact worth remembering every time a trusted voice online personally vouches for something.

Multi-level marketing

Multi-level marketing deserves particular scrutiny, because it layers a second business — recruiting other sellers — on top of the first. A 2024 Federal Trade Commission staff report, reviewing public income disclosures from dozens of MLM companies, found that most participants earned $1,000 or less per year, and that in at least seventeen of the companies reviewed, most participants earned no money at all. A separate AARP survey of MLM participants found that nearly half reported losing money on their participation once expenses were accounted for. The companies’ own recruiting materials, the FTC noted, consistently emphasized the small number of top earners while downplaying or omitting how the typical participant actually fared — a marketing structure built, in other words, using exactly the anecdote-over-evidence dynamic Chapter 3 of Book One examined in a different context.

The Supplement Dollar

Trace a single dollar spent on a supplement, and it typically splits several ways: a modest share to the actual ingredient and manufacturing cost; a meaningful share to marketing and customer acquisition, including affiliate and influencer commissions; a share to retail or platform margin; and, in an MLM structure, an additional share diverted upward through the recruiting hierarchy before it ever reaches the person who actually made the sale. Very little of that dollar is spent proving the product works.

Investigator’s Note

None of this means every supplement company is predatory, and it would be a mistake to read this chapter that way. It means the industry’s dominant business models — subscription revenue, affiliate commissions, and multi-level recruiting — all generate income from a sale independent of whether the product benefits the buyer, which is a structural fact worth knowing regardless of any individual company’s intentions.

The dollar amount behind a claim doesn’t just fund advertising. It funds a specific vocabulary designed to make marketing sound like research. That vocabulary is where we turn next.

Chapter 10 — Selling Science

“Pharmaceutical grade” sounds like a regulatory classification — a standard a product either meets or doesn’t, verified by someone with the authority to check. It isn’t. No federal agency defines or certifies “pharmaceutical grade” for a dietary supplement. A manufacturer can print the phrase on a label because it sounds rigorous, not because any body has confirmed the product meets a pharmaceutical standard of any kind. This chapter walks through that phrase and nine others like it — real words, borrowed from real science, deployed in ways science itself would rarely permit.

A glossary, decoded

“Clinically tested” and “research-backed” both imply a body of scientific literature stands behind the product. Neither phrase specifies how large that body of research is, how rigorous it was, or whether it was published anywhere a scientist could actually scrutinize it — the same gap Book One’s Chapter 2 identified in “clinically studied,” now recurring as a business practice rather than a one-off phrase.

“Physician formulated” means a doctor was involved in creating the product, in some capacity, at some point. It carries no implication that the formulation was tested, that the doctor has any relevant specialty, or that professional medical organizations endorse it.

“Pharmaceutical grade”, as this chapter opened by noting, has no regulatory definition for a supplement at all. It borrows the credibility of a real manufacturing standard used in actual drug production without being bound by any of that standard’s actual requirements.

“Third-party tested” can mean genuinely different things depending on who did the testing. Independent certification programs — NSF International, USP, and ConsumerLab among them — apply real, disclosed standards and are worth looking for by name. A company’s own paid lab, or an unnamed “independent” tester with no public standard or track record, can also technically satisfy the phrase “third-party tested” while providing a shopper almost no actual assurance.

“Scientifically formulated” and “evidence-based” both invoke the vocabulary of Book One’s Evidence Pyramid without specifying where on it the underlying research actually sits — often nowhere higher than a mechanistic theory or a single small study, the bottom rungs Book One’s Chapter 2 identified as where most marketing claims cluster.

“Bioavailable” is a legitimate pharmacological concept — describing how much of a compound the body actually absorbs and uses — deployed on labels almost universally without the specific bioavailability data that would make the claim meaningful or comparable between products.

“Detox” implies the product removes toxins your body couldn’t otherwise clear. In a person with normally functioning kidneys and liver — the organs whose actual job this already is — no supplement marketed under this term has been shown to meaningfully improve on what those organs already do; the term describes a function the body was already performing, sold back as a product.

“Cellular health” may be the vaguest phrase on this list, gesturing at biological legitimacy — cells are, after all, real and relevant to health — without making any claim specific enough to test, support, or refute.

Science Words Used in Marketing

Arrange these ten phrases side by side and a pattern emerges: each one borrows genuine scientific or regulatory vocabulary, strips it of the specific technical meaning that vocabulary carries in its original context, and redeploys it as an unfalsifiable signal of rigor. None of the individual words is fabricated. The rigor they imply, collectively, usually is.

None of this vocabulary requires an unusually persuasive expert to work — it works reliably even on skeptical, educated shoppers, because the words themselves are real and the underlying concepts are real. What makes this language so effective at commercial scale is a separate, newer phenomenon: the information ecosystem that now amplifies it to audiences of millions. The next chapter turns to that ecosystem directly.

Chapter 11 — The Influencer as Healthcare Advisor

A wellness podcaster with several million subscribers spends twenty minutes describing, in detail and with total confidence, a supplement protocol they credit with transforming their energy, their sleep, and their mental clarity. No medical license is mentioned, because none is required. No peer review precedes the episode. No disclosure requirement compels a clear statement of whether the podcast has a financial relationship with the brand being described — and when a disclosure does appear, it’s often a single line, spoken quickly, easy to miss entirely. By the time the episode ends, a portion of the audience has received what functions, in every practical sense, as a specific medical recommendation, from someone with no obligation to have gotten it right.

How someone becomes a healthcare advisor without meaning to

Book One’s Chapter 2 introduced influencer marketing as a channel; this chapter treats it as a role. A creator builds an audience around fitness, wellness, parenting, or general lifestyle content, develops a real relationship with that audience over months or years, and gradually becomes, in the audience’s eyes, a trusted source not just for opinions but for health decisions — a role no formal credentialing process ever assigned them, and one many creators occupy without any clinical training at all.

Why the algorithm rewards confidence over accuracy

Platforms from YouTube to TikTok to Instagram optimize for engagement — watch time, comments, shares — not for accuracy. Content that states a claim with total confidence and dramatic framing reliably outperforms content that hedges appropriately, cites uncertainty, or acknowledges mixed evidence, because confident, dramatic claims hold attention better than careful ones do. The result is a structural bias built into the distribution system itself: the algorithm doesn’t need to prefer misinformation on purpose. It only needs to prefer engagement, and engagement reliably correlates with certainty a topic like supplement science rarely earns.

Sponsorship and the affiliate link, revisited

Chapter 9 detailed the commission structure behind affiliate marketing; here, it’s worth naming what that structure does to the substance of the content itself. A creator whose income depends partly on affiliate commissions and sponsorships has a financial relationship with the products they discuss that most of their audience never sees modeled explicitly, and that relationship exists regardless of how genuinely the creator believes in the product — sincerity and financial interest are not mutually exclusive, which is exactly what makes the incentive so easy to overlook.

Podcasts, virality, and the absence of a gatekeeper

Long-form podcasts occupy a particular niche in this ecosystem: an hours-long, conversational format that feels less like advertising and more like overhearing an informed friend, precisely because no editor, fact-checker, or broadcast standard sits between the host and the microphone. A claim can go from a single episode to broad public awareness in days, entirely independent of whether anyone with relevant expertise has reviewed it first.

From Algorithm to Supplement Purchase

The pathway runs directly: a creator states a confident health claim → the platform’s algorithm amplifies whichever version of that claim performs best, which tends to be the most confident one → viewers, trusting the creator the way they’d trust a friend, click an affiliate link already built into the content → a purchase completes, generating revenue for the creator regardless of the claim’s accuracy, feeding directly back into Chapter 9’s economics.

Questions to Consider

Before acting on a health recommendation from a podcast, video, or influencer post, it’s worth asking directly: what is this person’s actual training in the subject they’re discussing? Do they disclose a financial relationship with the product, and if so, how prominently? And would the claim they’re making survive being stated in the more careful, hedged language Book One’s Evidence Ladder would require of it?

Fame changes this dynamic further, adding a layer of trust that has nothing to do with expertise at all. The next chapter turns to that effect directly.

Chapter 12 — The Celebrity Effect

An actor, an athlete, or a musician appears in an advertisement holding a supplement bottle, describing how it changed their life. Nothing about their career qualifies them to evaluate a health claim any more rigorously than anyone else. And yet, for a large share of the audience watching, their endorsement carries more persuasive weight than a peer-reviewed study would.

Why fame transfers trust that expertise didn’t earn

Psychologists call this the halo effect: a positive impression in one domain — talent, attractiveness, success, likability — bleeds into an unrelated domain where it has no logical claim to apply. An audience that admires a celebrity for their acting or their athletic achievement is prone to extend that same admiration, unconsciously, to whatever that celebrity happens to be holding up on camera. The transfer isn’t reasoned. It’s not supposed to be — it’s precisely what makes celebrity endorsement valuable enough to command the fees it does.

Parasocial relationships compound the effect. Audiences who have followed a celebrity for years, across interviews, social media, and public appearances, often feel they know that person in something like the way they know a friend — a one-directional relationship that nonetheless carries real emotional weight. A recommendation from someone who feels like a friend lands differently than an identical recommendation from a stranger, even when the underlying claim, and the underlying evidence behind it, hasn’t changed at all.

Celebrity → Trust → Claim → Purchase

The mechanism runs in a straight line: fame generates trust that has nothing to do with subject-matter expertise → that trust attaches to whatever claim the celebrity makes, regardless of its actual evidentiary basis → the claim reaches an audience primed to believe it specifically because of who’s making it, not what it says → a purchase follows, driven by the endorsement’s source rather than the product’s substance.

This is worth distinguishing clearly from Chapter 11’s influencer dynamic, even though the two overlap in practice. An influencer’s trust is typically built through sustained, topic-specific content — a fitness creator’s followers at least believe they’re getting fitness expertise, however unearned that belief may be. A celebrity’s trust is borrowed from an entirely unrelated domain, with no pretense of subject-matter relevance at all, which makes it, in a sense, the purer version of the mechanism this entire chapter is about: proof that a claim’s persuasiveness and a claim’s accuracy can be almost completely unrelated to each other.

Neither an influencer’s following nor a celebrity’s fame changes what a supplement’s actual evidence shows. What both changes is who’s listening, and how skeptically. The next Part of this book turns to a group whose skepticism should, in principle, be immune to exactly this kind of persuasion — physicians and pharmacists — and asks honestly whether it is.

PART VI — WHEN MEDICINE MEETS SUPPLEMENTS

Chapter 13 — What Do Physicians Know About Supplements?

A patient mentions, almost in passing, that they’ve started taking a new supplement. The physician nods, makes a mental note, and moves on to the medications actually listed on the chart. It’s a small moment, repeated in exam rooms across the country every day, and it reflects something larger than any individual doctor’s attentiveness: most physicians were never systematically trained to have this conversation in the first place.

A curriculum problem, not a competence problem

The National Academy of Sciences has recommended, since 1985, a minimum of 25 hours of nutrition education across a medical school curriculum. Surveys conducted over the following four decades have found American medical schools falling consistently short of that minimum — national surveys have found the average closer to 19 to 24 contact hours, with only about a quarter to a third of schools meeting the recommended minimum in any given survey year. A 2014 survey of primary care physicians found only about 14 percent felt adequately prepared to provide nutritional counseling to their patients. As of 2025, in response to sustained public and political pressure, more than fifty U.S. medical schools agreed to expand their nutrition curricula to roughly 40 hours — a meaningful shift, and also a clear acknowledgment of how far below that level most training had been running for decades.

Supplement-specific education fares no better, and in most curricula doesn’t exist as a distinct topic at all — it’s folded, unevenly, into whatever nutrition instruction a given school provides, which means a physician’s working knowledge of supplement pharmacology often depends heavily on which school they attended and what continuing education they’ve sought out voluntarily since.

Pharmacy education, a partial exception

Pharmacists generally receive more structured training in pharmacology and drug interactions than physicians do, including some coursework in herbal and supplement interactions specifically — my own field. But structured coursework and consistent clinical practice are two different things. A community pharmacist filling dozens of prescriptions an hour has limited time to conduct the kind of thorough supplement inventory Chapter 7 of this book described as ideal, even with the training to do it well.

Why patient disclosure breaks down

Patients frequently don’t volunteer supplement use unprompted, for a specific and understandable reason: they don’t think of a vitamin or an herbal product as “medication,” so a question like “what medications are you taking?” genuinely doesn’t call it to mind. The fix, as Chapter 7’s Professional Perspective sidebar noted, is not patient education alone — it’s a specific, direct clinical question: not “what medications,” but “what medications, vitamins, herbs, and supplements.”

Interaction checking has a blind spot

Most clinical decision-support software used to flag drug interactions was built primarily around prescription and over-the-counter drug databases. Supplement coverage in these systems has improved but remains inconsistent, particularly for newer or less common botanical ingredients — which means even a conscientious clinician doing everything right can run an interaction check that simply has no entry for the product their patient is actually taking.

Professional Perspective

I spent sixteen years managing medication safety systems built to catch exactly the kind of interaction described in Chapter 7 — systems that worked well for the medications they were designed to track. What they were never built to track was a category of product patients don’t think to mention, that pharmacy training addresses unevenly, and that decision-support software often doesn’t fully cover. Closing that gap doesn’t require distrusting supplements as a category. It requires building the same systematic attention around them that medicine already applies to everything else a patient takes.

This gap becomes most visible, and most consequential, in a specific and increasingly common patient: someone managing not one supplement alongside their medications, but ten or twenty. The final chapter of this book turns to that patient directly.

Chapter 14 — The Patient Who Takes Everything

Picture a patient in her late sixties, managing high blood pressure, mild osteoarthritis, and borderline cholesterol — three prescription medications in total. Alongside them, a supplement drawer holds a multivitamin, fish oil, glucosamine and chondroitin, turmeric, vitamin D, magnesium, a probiotic, CoQ10, and a greens powder she adds to her morning smoothie. Nine products, taken daily, none of them prescribed, none of them reviewed together by anyone as a complete regimen. This is not a rare or extreme case. It’s an increasingly ordinary one — and it’s the patient this entire book has been building toward.

Why the whole is riskier than any single part

Every risk this book has documented — interactions, dose accumulation, contamination, mislabeling — compounds when multiplied across nine or ten products taken simultaneously rather than one. A single supplement’s interaction risk with a given medication might be modest. Nine supplements, each carrying its own small, independent risk, create a combinatorial space of possible interactions that no consumer, and frequently no clinician working from an incomplete list, is realistically tracking. Fat-soluble vitamin accumulation from Chapter 8 becomes more likely when several products in the regimen happen to include overlapping ingredients — a multivitamin and a separate vitamin D supplement, a greens powder and a separate vitamin C tablet — without anyone totaling the combined dose.

Why this patient rarely gets asked the full question

Return to Chapter 13’s central finding: physicians are inconsistently trained to ask about supplements at all, and patients rarely volunteer them unprompted because they don’t file vitamins and herbs under the mental category of “medication.” A patient taking nine supplements alongside three prescriptions may walk into an appointment having mentally rehearsed only the three.

A tool, not just a diagnosis

This book has spent thirteen chapters documenting a problem. This final chapter offers one concrete tool toward closing it: a simple medication and supplement reconciliation worksheet, meant to be filled out before an appointment and brought in, covering everything a patient takes — prescribed and not — in one place.

“What Are You Taking?” — A Medication and Supplement Inventory

Fill in every product you take regularly, prescribed or not. Bring this list to every medical appointment.

Before your appointment, ask yourself:

• Have I added anything new to this list since my last visit?
• Do any of these overlap — two products containing the same vitamin or mineral?
• Have I mentioned all of these to every provider I see, not just one?

At your appointment, ask your provider directly:

• Do any of these interact with each other or with my prescriptions?
• Am I taking more of any single nutrient than I need, once everything here is added up?
• Is there anything on this list I could safely stop taking?

Recommended Illustration: a visual “Medication + Supplement Inventory” — every product a patient takes, prescription and supplement alike, laid out on one page rather than split across the mental categories of “medicine” and “health product,” making the true scale of a regimen visible at a glance.

— End of Book Two —

This book set out to answer the question Book One left open: how much of what fills an American medicine cabinet has actually been tested, regulated, or reviewed the way the beta-carotene trials tested a single vitamin three decades ago? The honest answer, chapter by chapter, has been: less than the label implies, less than the marketing suggests, and less than most patients — and a fair number of their physicians — currently assume.

None of this is an argument to empty the cabinet. It’s an argument for treating every bottle in it with the same seriousness this book has applied throughout: read the label past the front-of-package claim, ask what evidence actually exists, disclose everything to every provider, and remember that “natural” was never a safety test.

Book Three turns from diagnosis to application — testing this framework against real chronic disease claims, the information ecosystem that spreads them, and a set of documented case files — and closes with a specific recommendation for what should actually change.

How This Book Sources Its Claims

Every factual claim in this book is sourced — to peer-reviewed research, federal regulatory documents, or government data. Where a figure represents an estimate or a range rather than a single precisely observed count, this book says so, and reports the range rather than a single headline number that would sound more certain than the underlying research actually is. The full bibliography follows this note.

If you believe a citation in this book has been misrepresented, I want to know — reach out through Coleman Publishing or brokenpromiseshealthcare.org, and it will be reviewed.

Bibliography

Dietary Supplement Health and Education Act of 1994, Public Law 103-417, 103rd Congress.

U.S. Food and Drug Administration. “Structure/Function Claims.” FDA.gov.

U.S. Food and Drug Administration. “Dietary Supplements.” FDA.gov.

U.S. Food and Drug Administration. CFSAN Adverse Event Reporting System (CAERS) data, 2004–2021.

U.S. Food and Drug Administration. Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated, 2004.

Navarro, Victor J., et al. “Liver Injury From Herbals and Dietary Supplements in the U.S. Drug-Induced Liver Injury Network.” Hepatology 60, no. 4 (2014): 1399–1408.

Ruschitzka, Frank, et al. “Acute Heart Transplant Rejection Due to Saint John’s Wort.” The Lancet 355, no. 9203 (2000): 548–549.

U.S. Federal Trade Commission. Staff Report on Multi-Level Marketing Income Disclosure Statements, 2024.

DeLiema, Marguerite, et al. AARP Foundation Study of Multilevel Marketing: Profiling Participants and Their Experiences in Direct Sales. AARP Foundation, 2018.

Adams, Kelly M., et al. “Status of Nutrition Education in Medical Schools.” American Journal of Clinical Nutrition 83, no. 4 (2006): 941S–944S.

National Academy of Sciences, Committee on Nutrition in Medical Education. Nutrition Education in U.S. Medical Schools. National Academies Press, 1985.

National Public Radio. “Medical Schools Agree to Expand Their Nutrition Curriculum,” 2025.

About the Authors

Joy Meier, Pharm.D.

[Placeholder — bio to be supplied. Suggested elements to include: clinical background and credentials, current or most recent practice setting, relevant specialization (e.g., ambulatory care, nutrition, clinical pharmacology), any supplement- or dietary-science-specific expertise or publications, and how she came to co-author this investigation.]

Robert W. Coleman, MS Pharm.

Robert W. Coleman spent forty years in medicine, sixteen of them as Director of Clinical Pharmacy Services at the VA Palo Alto Health Care System, where he ran medication safety programs for tens of thousands of veterans. His peer-reviewed research spans infectious disease, pharmacokinetics, anticoagulation therapy, and medical informatics.

He writes as an investigator, not an advocate. The Hollow Aisle is the second volume of The American Supplement Investigation, a companion series to his healthcare-financing trilogy, The American Healthcare Investigation. His work is published under the Coleman Publishing imprint and can be found, alongside his full research library and sourcing archive, at brokenpromiseshealthcare.org.